Patient Reported Outcomes of Medical Cannabis for Managing Pain in Charcot-Marie-Tooth Disease

Introduction

Charcot-Marie-Tooth (CMT) disease is the most common genetic neuropathy affecting 1 in 2,500 people [1]. Although the motor symptoms may attract the most attention, a large survey (N = 407) revealed that over three-quarters of patients with CMT experienced pain and over four-fifths numbness [2]. Among genetically diagnosed patients with CMT1A, 29% had neuropathic pain. Allodynia was the most specific neuropathic pain symptom [3]. Complications of CMT include sleep apnea, restless legs syndrome, daytime sleepiness, and impaired sleep [4].

Although there is no known cure for this slowly progressive disease, there are treatments such as physical and occupational therapy, orthotics, and pharmacotherapies to manage symptoms. The medications used for pain management are varied and included aspirin, nonsteroidal anti-inflammatory medications, acetaminophen, tricyclic antidepressants, anticonvulsants, and opioids [5].

The National Academy of Sciences reported that there was conclusive evidence indicating that cannabis was effective for chronic pain among adults [6]. There was also moderate evidence that cannabis was effective for improving short-term sleep outcomes in individuals with sleep disturbance associated with obstructive sleep apnea syndrome or chronic pain [6]. Clinical-practice guidelines are now emerging recommending that chronic pain patients can be treated with medical cannabis [7]. Surveys of cannabis dispensary members have identified a harm-reducing substitution effect where they reduce or stop using other medications, especially opioids [8], after starting cannabis. There is currently no published information about medical cannabis that is specific to CMT. The objective of this exploratory study was to obtain CMT patient’s perspectives regarding the benefits and risks of medical cannabis.

Materials & Methods

Results

Issues related to muscle weakness and atrophy were common in this sample. About three-quarters of respondents reporting weak ankles (72.2%), about one-third with muscle atrophy (36.1%), tremors (33.3%); a quarter had poor or absent reflexes (27.8%), clumsiness (25.0%), coordination or balancing problems (25.0%), restless leg syndrome (25.0%), arm or leg weakness (22.2%), difficulty with physical activity (22.2%), rigid muscles (22.2%); and a fifth had hammer or curled toes (19.4%), spasticity (19.4%), and weakness (19.4%). Sensory concerns included temperature sensitivity (27.8%), neuropathic pain (22.2%), and numbness (22.2%).

Preferred methods of cannabis consumption were smoking (34.0%), vaporize (28.3%), edibles (26.4%), sublingual tinctures (7.6%), and topical (3.8%). Preferred strains were indica dominant (22.2%), 50/50 THC/CBD (20.4%), high CBD (16.7%), high THC strains (9.3%), sativa dominant strains (5.6%), and hybrid strains (3.7%). One-third (33.9%) possessed a medical cannabis certificate.

When asked if they experienced pain associated with CMT, 90.9% of participants answered ‘yes’. All (100%) females but only 72.7% of males reported pain associated with CMT (chi-square p < .05). In response to: ‘How effective is medical cannabis in alleviating your symptoms with CMT?’ respondents provided the percent of relief they experienced from medical cannabis (0 to 100% in 10% increments). The most frequently selected option was 80% relief. The vast majority (91.7%) indicated cannabis provided at least 50% relief (Figure 1A).

• Download figure
• Open in new tab

Figure 1.

Charcot-Marie-Tooth patients’ (N = 56) evaluations of medical cannabis. Percent symptom relief (mean = 69.6, SEM= 2.6) from medical cannabis (A). Percent reporting a reduction in medication use after using medical cannabis (B). Percent that informed health-care providers of cannabis use based on perceived support (C, *p < .05 versus unsupportive).

Participants were asked if they noticed a change in their use of other medications after they began using medical cannabis. Among the subset that used each drug class, four-fifths (80.0%) reported using less opiates, two-thirds (68.8%) with less sleep medication, and half (50.0%) with less anxiety medications or less antidepressants (47.8%, Figure 1B).

Physicians’ attitudes regarding patient medical cannabis use were examined. For those who reported receiving a supportive response from providers, three-fifths (63.6%) indicated that they would inform them of their medical cannabis use. For those who reported unsupportive responses from providers for medical cannabis use, less than one-fifth (18.8%) said they would inform providers of their cannabis use (p < .05, Figure 1C,).

Participants reported whether they experienced negative side effects due to cannabis use (23.5% do) and if they planned on halting their usage (2.0% answered ‘yes’ and 9.8% ‘unsure’). The preponderance who did (91.7%) as well as most who did not (87.2%) have negative side effects did not have plans to stop consuming medical cannabis.

Discussion

This is the first study examining patients with CMT perspectives regarding MC. Patients with CMT reported that medical cannabis provided marked symptom relief. Based on the substantial (70%) improvement in CMT symptoms, cannabis may be a promising therapeutic option if these findings are verified with prospective or randomized controlled trials. These findings extend upon prior research with cannabinoids as complementary and alternative therapeutic agents for other neurological conditions [6, 10]. The results for multiple-sclerosis appear to be formulation dependent [11, 12]. The American Academy of Neurology reports that there is high quality evidence indicating that oral cannabis extract is efficacious in relieving symptoms of spasticity and pain in patients with multiple sclerosis. There were also concerns about adverse effects as well as the use of non-standardized cannabis extracts [13].

Perceived provider attitudes may adversely affect patients’ likelihood to inform providers of their medical cannabis use. There have been some, mostly regionally focused, efforts to characterize providers attitudes towards medical cannabis [14-16], particularly among medical oncologists [17-18]. Medical cannabis is a controversial topic and the likelihood of an open-dialogue between patients and providers likely varies based on provider specialty, region of the country, and employer policies [8, 17, 19]. Cannabis was viewed by these patients as a therapeutic drug and, as such, it is crucial that they are able to inform their medical providers of their use.

This report also determined that four out of five CMT patients reported decreasing their use of opiates after starting medical cannabis. Similarly, two-thirds (68.8%) reported less sleep medication, and half (50.0%) with less anxiety medications or less antidepressants (47.8%). The identified substitution effect corroborates prior investigations including among New England dispensary patients primarily with chronic pain [8], Prescription Drug Monitor Program records in New Mexico [20] and Medicare and Medicaid prescription records [21, 22]. However, recent ecological research has challenged whether this substitution effect meaningfully impacts opioid overdoses [23, 24]. Regardless, there would appear to be some harm reduction impact of cannabis by allowing patients to take less opioids. However, further attention is needed if those that use less prescription medications (e.g. antidepressants) are also not informing their health care providers.

Also noteworthy was that only one-third of participants in this study were certified for medical cannabis. The demarcation between medical and recreational cannabis use is likely complex [8] as some “medical users” may use it for recreational purposes and some “recreational users” may be self-treating for therapeutic purposes. The cost of medical cannabis is non-trivial and is not covered by insurance.

There are a number of notable limitations to this study. Inherent to survey studies is respondent bias. All participants (N=56) in this study use cannabis. Given the branched design of the survey, there were multiple questions where fewer than twenty respondents provided information. This would bias the dataset toward a positive cannabis experience as those who are more inclined to answer the survey generally have more favorable experiences with medical cannabis. Although the sample size (N = 56) was only moderate, CMT is a relatively rare disease [1] making these findings particularly novel relative to the absence, to our knowledge, of prior investigations. Cannabis not being used in a controlled setting (dosage, composition, methods of delivery, etc.) was also a limitation. Cannabis can be administered in many ways, whether it is inhaled through vapor or ingested in food or drinks and each method has a different rate of absorption. Although some participants reported a decrease in their pain, there is no indication as to how much cannabis they consumed in order for them to see that decrease. It is possible that those who reported decreased levels of pain consumed an increased dose of cannabis and/or had a different method of administration that was faster at relieving pain than that of those participants who reported no change in their pain levels. Prospective or controlled studies with a standardized product, dose, and limited route(s) of administration will be necessary to further evaluate the risks and benefits of medical cannabis for CMT.

Conclusions

The findings from this survey indicate CMT patients report that cannabis may provide substantial symptom relief. These novel results, in conjunction with prior research, may warrant further prospective or controlled study of MC for pain management.

Grant Disclosures

BJP was part of an osteoarthritis research team supported by Pfizer and Eli Lilly (2019-2021) and is supported by the Pennsylvania Academic Clinical Research Center and Health Resources Services Administration (D34HP31025). CMS, AW, and MD are employed in the cannabis industry. The other authors report no disclosures.